Plasma Resilience: Europe's Lifeline
Human plasma, a protein-rich liquid making up 55% of our blood, is crucial for developing therapies for various conditions, including rare inherited disorders and immunodeficiencies.
Despite its importance, Europe's plasma supply chain is vulnerable due to its reliance on human donation, with over 12 million people donating plasma annually under rigorous safety standards.
However, this is not enough, as nearly 40% of plasma used for European medicines is imported from the United States.
Each year, more than 12 million people across Europe donate plasma through a process governed by rigorous safety standards set by EU Member States.
The Plasma Protein Therapeutics Association (PPTA) and international safety standards, such as the International Quality Plasma Program (IQPP), oversee the donation process.
Autor's resume: Europe needs to strengthen plasma resilience now.
More News
- Marine communications experts were 'Thunderstruck' in first-ever competition
- Your Next Sunshine Coast Escape Just Got Way Cheaper Thanks To This Epic Flight Deal
- Harvest 2025 in review – NFU Crops Board members share their thoughts
- Acquisition of Aligned Data Centers by a BlackRock-led Consortium - TechStory
- FCA’s targeted support proposals are limited but still worthwhile
- Bob Ross paintings to hit auction block as fundraiser for APT’s Create
- Charlie Kirk and the Free Speech Hoax
- How E-Bikes Are Redefining Outdoor Entertainment & Leisure | NorthPennNow
- Kada Scott: Vehicle found, arrest made after 23-year-old Philly woman vanishes
- Plasma resilience: Europe’s lifeline — and why we must strengthen it now